This website uses cookies to ensure you get the best experience on our website. Learn more

Amy Flaxman: Antibody responses to viral-vectored coronavirus vaccines

x
  • Post Vaccination Antibody Testing: Its Role for Determining Level | Benjamin Larimer, PhD

    20:40

    Lecture: Post Vaccination Antibody Testing: Its Role for Determining Level
    Speaker: Benjamin Larimer, PhD
    University of Alabama at Birmingham, United States of America
    Presented at: COVID-19 Vaccine Development & Implementation Workshop 2021 | February Edition

    Learn more about the next COVID-19 Vaccine Development & Implementation Workshop edition that will take place on 29 - 30 June 2021 via

    The COVID-19 Vaccine Development & Implementation Workshop aims to increase knowledge and facilitate discussion on the many aspects of vaccine development and rollout on a background of a firm understanding of pathogenesis and natural infection. Our goal is to address the many scientific, social, and policy challenges in the totality of delivering an effective COVID-19 vaccine.​

    For more medical education programs, as well as the latest scientific information, visit

  • x
  • Webinar: Responding to Emerging SARS CoV 2 Variants

    58:29

    Webinar: Responding to Emerging SARS-CoV-2 Variants - The Impact on Existing Diagnostic Testing and the Clinical Utility of Differentiation Assays

    As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus. Understanding the impact of these variants on molecular testing methods and how labs can address this added complexity is important to managing the diagnostic response to the ongoing pandemic.

    In this webinar Dr. Martin Stürmer discusses the effects of emerging SARS-CoV-2 variants on diagnostic methods and the clinical utility of detecting and discriminating them. Thomas Alef will then present how their clinical lab was able to react to the emergence of new, often more contagious, variants of the virus by rapidly designing a highly multiplexed SARS-CoV-2 variant panel using the low-cost, high-throughput MassARRAY System from Agena Bioscience.

    Speakers:

    Martin Stürmer, PhD
    Laboratory Head , IMD Labor Frankfurt

    Thomas Alef
    Biologist, Seq-IT

    Darryl Irwin, PhD
    Vice President, Scientific Affairs, Agena Bioscience

  • x
  • New variant of Covid 19 may be twice as transmissible as earlier strains

    1:52

    The P.1 coronavirus variant first identified in Brazil may be twice as transmissible as earlier strains and may evade up to nearly half of immune defences built during previous infections, a new study suggests.

  • Laboratory Management Strategy for Covid-19

    2:23:36

  • x
  • Amy Flaxman: Antibody responses to viral-vectored coronavirus vaccines

    31:17

    Dr Amy Flaxman is part of the Oxford Vaccine Group, Jenner Institute, University of Oxford. For her post-doctoral research she has worked on both pre-clinical studies developing vaccines for outbreak pathogens, such as Ebola, and clinical trials for outbreak pathogens, including MERS and Ebola. She is currently investigating immune responses to the Oxford ChAdOx1-nCoV vaccine for SARS-CoV-2 that was in Phase III clinical trials but is now approved. She leads the lab team carrying out antibody testing post-vaccination. Here, she is interested in the differences in antibody responses induced over time with different doses of vaccine, in different age groups and how this changes with administration of a booster vaccine.

  • Antibody response following SARS-CoV-2 vaccination

    4:48

    In this second video about SARS-CoV-2 (COVID-19) antibodies, vaccination and infection, Professor Lawrence S. Young, from Warwick Medical School UK, and internationally recognised for his work in virus infection, discusses the antibody response following SARS-CoV-2 (COVID-19) vaccination.

  • x
  • Katie Ewer: T cell responses to the Oxford / AZ COVID-19 vaccine in UK clinical trials

    25:43

    Katie Ewer is Associate Professor and Senior Immunologist at the Jenner Institute, University of Oxford where she leads a program of exploratory immunology studying vaccine-induced immunity to malaria and outbreak pathogens, such as Ebola, MERS and now SARS-CoV-2. A key aim of her research is focused on characterizing T cell responses induced by vaccination with viral vectors. During the COVID-19 pandemic, she played a pivotal role in the clinical trials in an effort to find a vaccine, which has led to the successful roll-out of the first approved SARS-CoV-2 vaccine, ChAdOx1 in partnership with AstraZeneca in December 2020. In this talk she explains how the vaccine was developed in record-breaking time, the characterisation of the immune responses to the vaccine and the forthcoming challenges still faced including the question of booster doses, manufacturing and supply and how we respond to the next inevitable pandemic.

  • Can You Overdose On COVID Antibodies? Dr. Mallika Marshall Answers Your Vaccine Questions

    2:08

    Dr. Mallika Marshall is answering your coronavirus vaccine-related medical questions.

  • No-Cost COVID-19 antibody tests

    6:08

    A nonprofit organization is partnering with the community and businesses to offer no-cost COVID-19 antibody tests.

  • x
  • Contribution of COVID Antibodies as an Adjust test for diagnosis of Acute COVID-19 infection

    1:1:38

  • Optimizing Diagnostics for Post Vaccination Surveillance | Sanjat Kanjilal, MD, MPH

    19:55

    Lecture: Optimizing Diagnostics for Post Vaccination Surveillance
    Speaker: Sanjat Kanjilal, MD, MPH
    Brigham & Women’s Hospital, Harvard Medical School &
    Harvard Pilgrim Healthcare Institute, United States
    Presented at: COVID-19 Vaccine Development & Implementation Workshop 2021 | February Edition

    Learn more about the next COVID-19 Vaccine Development & Implementation Workshop edition that will take place on 29 - 30 June 2021 via

    The COVID-19 Vaccine Development & Implementation Workshop aims to increase knowledge and facilitate discussion on the many aspects of vaccine development and rollout on a background of a firm understanding of pathogenesis and natural infection. Our goal is to address the many scientific, social, and policy challenges in the totality of delivering an effective COVID-19 vaccine.

    For more medical education programs, as well as the latest scientific information, visit

  • NJ hospital offers first-ever test for COVID antibodies post-vaccine

    1:33

    Just like the regular antibody test, blood is drawn but in this case the analysis zeros in on the “spike protein” or in simple terms — the vaccine-generated antibodies instead of the natural ones developed after infection.

  • Mid-Michigan reacts to Pfizer’s announcement about vaccine effectiveness on young teens

    1:31

    Pfizer clinic trials report its COVID-19 vaccine is 100 percent effective in people aged 12 to 15.

  • Sequencing to fight COVID-19

    4:49

  • CREST Poster Session April 10, 2021 - SARS-CoV-2 proteins

    1:27:56

    The CREST (Connecting Researchers, Educators and Students) Project is an NSF funded program in which undergraduate students work with faculty advisors and research mentors to explore a current research topic in detail. They use 3D printing to build physical models of proteins to tell a molecular story of how the protein works. This year teams explored proteins of the SARS-CoV-2 virus, which is the cause of the Covid-19 pandemic. The teams present their projects in a virtual meeting in this video.

  • Some Puget Sound pharmacies displaying outdated COVID-19 vaccine requirements

    2:03

    Several pharmacies providing the COVID-19 vaccine in Washington have been booking appointments based on outdated eligibility guidelines. That's concerning to health officials and equity advocates who acknowledge it's already difficult enough to find an appointment.

    Washington opened vaccine eligibility to Phase 1B, Tiers 3 and 4 on Wednesday, March 31, which expanded coverage to about two million more people.

    However, as of Thursday morning, CVS, Albertsons/Safeway and Rite-Aid listed incomplete or incorrect eligibility criteria on their websites to book appointments. Without passing these flawed surveys, it is impossible to book an appointment on these websites.

  • COVID-19 Vaccine Diversity Series: Do I need the vaccine if Ive already had COVID-19?

    1:15

    Dr. Nicole Sleiman tackles the next question in Mercy's COVID-19 Vaccine Diversity Series: Do I need the vaccine if I've already had COVID-19?

    If you have a question specific to this diversity series that you'd like to see answered, please email it to COVIDVaxQuestions@mercy.net.

  • The CDC Wants To Know About Your COVID-19 Vaccine Side Effects

    1:52

    A smartphone-based program from the Centers for Disease Control and Prevention wants to know how COVID-19 vaccine recipients are feeling and if they are having any side effects.

  • Should you get an antibody test to see if your COVID vaccine worked? #shorts

    46

    GERI-Minute #145 Do you need an antibody test after your COVID vaccine? Will it tell you if your vaccine worked?
    I don't recommend antibody tests after a vaccine.
    Antibody tests don't tell us everything about the immune system, so shouldn't be relied upon to show that a vaccine has worked when it comes to COVID.

    ***If you like our content please LIKE, SUBSCRIBE and COMMENT! ***
    And find more like this at

    Like us on Facebook –
    Join us on Twitter - @TheWrinkle2
    Send us an email at wrinklechat@gmail.com
    And here on YouTube - Please like and subscribe – it’s FREE!

  • Ive had COVID, do I still need the vaccine? || COVID Vaccine Update

    5:49

    In this COVID 19 vaccine update, I answer a common question regarding the vaccine: I've had COVID, do I still need the vaccine? A recent JAMA article provides data to support the answer, unequivocally, YES!



    ------------------------------------
    WEBSITE:
    FACEBOOK:
    INSTAGRAM:
    TWITTER:

    This video is for educational purposes only. It is not intended to diagnose or treat any condition in any way. Always consult a medical professional for matters concerning your personal health.

    #covid19 #covidvaccineupdate #coronavirus

  • x
  • Covid Conversations Ep13: Should I be concerned if my lymph nodes are swollen after my vaccine?

    7:09

    COVID-19 vaccinations can cause harmless enlarged lymph nodes, usually under the arm and on the side the shot was given. For those who have previously had cancer or who are due for a regular mammogram screening, this swelling can cause confusion, even stress and anxiety.

    Julie A. O'Brien, M.D., F.A.C.S., Breast Surgeon at Lahey Hospital & Medical Center and Director of Lahey’s Comprehensive Breast Health Center joins Covid Conversations to answer the question Should I be concerned if my lymph nodes are swollen after my vaccine?

  • Gyrolab Serological Immunoassay for the Rapid, Qualitative Analysis of COVID-19 Antibodies

    6:18

    Serology immunoassays detecting antibodies against COVID-19 in human serum are needed with high sensitivity, high throughput capabilities, low reagent and sample use, and rapid assay times. Gyrolab immunoassays providing qualitative analysis of antibodies against COVID-19 in human serum for community screening and for vaccine development applications are now available to meet these needs. Gyrolab miniaturized, microfluidic, CD-based immunoassays dramatically reduce the sample and reagent volumes, with a rapid time to data of about 1 hour. The immunoassays are fully automated with minimal hands-on time and are designed for 21 CFR Part 11 compliance in regulated environments.

    The Gyrolab COVID-19 serology immunoassay is available for the qualitative detection of total antibodies (IgG, IgA, and IgM) generated against the spike protein receptor binding domain (RBD) of
    SARS-CoV-2 in human serum samples. The bridging immunoassay format consists of a biotinylated RBD-His as capture reagent, and Alexa 647 labelled RBD-Fc detection reagent. Gyrolab immunoassays are fully automated, producing data in about an hour.

    The specificity of the immunoassay to antibodies against SARS-CoV-2 was evaluated by analyzing serum samples from 50 individuals collected pre-pandemic in comparison to negative and positive controls. The pre-pandemic serum samples all tested within the same range as negative controls, with an assay response for serum samples spiked with positive controls also in the expected ranges. The Gyrolab assay produced 112 data points in one hour using only 4 µL of sample required per datapoint. The SARS-CoV-2 antibody assay has a broad dynamic range from 40 ng/mL to 200 μg/mL.
    Gyrolab SARS-CoV-2 antibody immunoassay saves sample and reagent volumes and time and provides a broad assay dynamic range. The protocol, available on the Gyros Protein Technologies website, saves development time and reduces reagent use. Gyrolab is an open system and can be used for other SARS-CoV-2 antibody immunoassay formats.
    Antibody therapeutics development for COVID-19 treatment includes interest in repurposing approved cytokine inhibitors to prevent or dampen the hyperinflammation seen in patients infected with COVID-19. Among the FDA-approved interleukin inhibitors being investigated for repurposing, Actemra is currently in Phase III clinical studies for the prevention of acute inflammatory response. The Actemra Gyrolab PK assay protocol can accelerate bioanalysis in IL-6 inhibitor clinical development.
    For more information on Gyrolab immunoassays, visit

  • ChAdOx1 Vaccine COVID-19: Another Vaccine Reaching Phase 1/2 Trials, Was It Safe And Did It Work?

    18:11

    WhiteBoard style discussion on another vaccine (we previously did a video on the Moderna Vaccine) that just completed Phase 1 and Phase 2 Trials published in Lancet. They are using a adenovirus model that is replication deficient and gave this adenovirus the SARS-CoV-2 spike protein. This was a model that was proven safe and affective for MERS previously. They compared this to a meningococcal vaccine in 1,077 patients. They focused on the safety profile and efficacy, specifically IgG titers to the SARS-CoV-2 spike protein, several neutralization assays against live SARS-CoV-2, and T cell responses. Check out the video for all the details on the results!

    PLAYLIST ON ALL OF OUR VACCINE/COVID-19 CONTENT TO DATE:

    We have just recently debuted a Patreon page with exclusive perks, WhiteBoard Doctor merchandise, and more! Come check it out and consider becoming a WBDR Patreon!


    Link to study:


    Link to Moderna Vaccine video:


    There will be a running series of videos using the most up to date information on COVID-19, but this is an evolving field and new videos may come out that contradict that previous information. That is okay and is the nature of a fast paced and evolving clinical scenario. Stick with us as we work to unveil the intricacies of COVID-19, it's clinical significance, and the societal implications. ***This is strictly educational and not to be mistaken as clinical recommendations, please verify all information with accepted guidelines and practice patterns.***

    DISCLAIMER
    THIS VIDEO DOES NOT PROVIDE MEDICAL ADVICE. The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read, watched, or listened to on this video, or any other videos, reports, texts tweets or other sources.

  • Johns Hopkins doctor reacts to Pfizer vaccine study on ages 12 to 15

    1:48

    A breakthrough in the push to vaccinate the country as Pfizer says its COVID-19 vaccine has been shown in a clinical trial to be 100% effective on children as young as 12-years-old.

    Subscribe to WBAL on YouTube now for more:

    Get more Baltimore news:
    Like us:
    Follow us:
    Instagram:

  • Arlene Sharpe: Roles of the PD-1 pathway in controlling tolerance & tumor immunity

    50:03

    The immune response plays an important role in fighting cancer; however, the tumor environment is immunosuppressive and limits effective anti-tumor immunity. A new and promising strategy of tumor immunotherapy blocks pathways used by tumors to inhibit anti-tumor immunity. This inhibitory strategy is called checkpoint blockade. One key immunoinhibitory pathway that inhibits tumor specific immunity is the PD-1 co-inhibitory pathway. This pathway consists of the PD-1 receptor and its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC). The PD-1 pathway plays critical roles in maintaining immune control, and is a key mediator of T cell dysfunction (“exhaustion”) in cancer and chronic infections. This pathway is a promising therapeutic target in cancer. The remarkable effects of PD-1 pathway blockade in cancer demonstrate the key role of this pathway in inhibiting anti-tumor immunity. However, there are multiple co-inhibitory pathways that that limit T cell function, and these have become targets for cancer therapy. This talk will discuss the multifaceted immunoregulatory roles of PD-1 and its ligands in controlling T cell activation, tolerance and exhaustion. The role of the PD-1 pathway in cancer as well as therapeutic strategies that combine PD-1 blockade with other therapies also will be discussed.

  • Manolis Kellis at Athens Science Festival 2021 - Dissecting Disease Circuitry

    1:23

    0:00 Intro by Athens Science Festival organizers
    2:23 Intro by moderator Zoe Cournia
    4:17 Intro in Greek then English
    4:44 Intro to GWAS and my AMD predisposition
    5:47 Bridging the gap between SNPs and Disease
    6:50 Promise of Genetics and Challenge of Interpretation
    9:09 Integrate Genetics, Epigenomics, RNA, Algorithms, Validation
    14:11 Single-cell profiling across traits, individuals, tissues, cell types
    16:37 Integration with Bayesian, Causality, Deep Learning, Mediation
    18:53 Inferring circuitry of FTO Obesity Locus: ARID5B, IRX3/IRX5, Thermogenesis
    23:32 Manipulate circuitry to reverse disease phenotypes
    26:16 EpiMap: 834 tissues/cell types to interpret 30,000 GWAS loci
    26:30 Partitioning complex disorders: Coronary Artery Disease
    27:27 Single-cell dissection of Alzheimer's Disease
    29:20 Single-cell dissection of Schizophrenia
    30:54 Multi-region spatio-temporal Alzheimer's Progression
    32:16 Spatial Transcriptomics and Single-cell Integration
    33:20 Microglia subtypes: Synaptic/Inflammatory in Schizophrenia/Alzheimer's
    33:38 Vasculature zonation in blood-brain barrier breakdown in neurodegeneration
    34:02 Coordinated changes in RNA and DNA accessibility
    34:32 Excitatory/Inhibitory neurons in schizophrenia vs. Microglia in Alzheimer's
    35:00 Multi-tissue multi-omics of exercise/diet in human/mouse: Adipocyte Stem Cells and T-cells
    36:55 Cancer progression during immunotherapy samples
    37:28 Electronic Health Record integration with Genomics
    37:57 Ultra-high-throughput assays: 7M tests in a single experiment
    38:43 Modular and programmable CRISPR-Casa9/dCas9 enhancer/gene modulation
    39:49 COVID-19 and SARS-Cov-2 genome annotation and mutation interpretation
    41:48 Importance of Academic Collaborations and Industry Partnerships
    42:15 Seeking new postdocs for new grants in disease dissection
    42:58 Q&A: Interpreting one's own genome, addressing predispositions
    45:30 Importance of supporting science and scientific research
    46:10 Limits of genetic prediction, importance of healthy lifestyle
    47:57 Short-term vs. long-term impact of research and disease circuitry dissection
    48:56 Role of AI in disease understanding/prediction, role of hardware architectures
    50:40 Bioethics of predisposition, prediction, embryo selection; importance of diversity
    53:24 AI for personalized behavioral recommendations from genomic datasets; exercise
    55:18 Long-term effects of vaccines, drugs. Vaccines are safe
    58:12 Goodbyes and wrap-up
    58:38 High-throughput validation, facility requirements, computational thinking

  • Dr Sarah Bergin, Consultant Microbiologist in Naas General Hospital receives her COVID-19 Vaccine

    21

    WATCH: Dr Sarah Bergin, Consultant Microbiologist in Naas General Hospital received her #COVIDVaccine today. Sarah asks everyone to #StayHome & #StaySafe. Protect yourself & others from #COVID19


    (January 7th 2021) Staff Nurse Cindy Morga was the first person in Naas General Hospital to be vaccinated with the Pfizer BioNTech COVID-19 Vaccine against COVID-19. She was vaccinated by her colleague Maeve Fitzgerald, Clinical Nurse Manager Health and Wellbeing.

    Staff vaccinations started today at the Hospital with plans to deliver the 1st dose of the vaccine to all staff. A peer vaccination team of up to 7 nurses will vaccinate staff Monday to Saturday ensuring that all personnel are protected in a planned and timely way.

    For more info:

  • CANADA Update: Canada Temporarily Suspends Oxford AstraZeneca Vaccine for people under 55

    16:23

    This video is to clarify the reasons behind concerns with the Oxford/AstraZeneca Vaccine, that have prompted Canada's National Advisory Committee on Immunization to suspend its' use temporarily as of today, March 29, 2021.
    This is difficult news but it is important that safety signals observed by international surveillance are acted up and that any risk to the public is assessed and fully investigated before proceeding.




    Friendly Pharmacy 5 is sponsored by Heart Pharmacy. For more updates and relevant Health Information, sign-up for their newsletter at

    Why Canada is Suspending the AZ Vaccine:


    A Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia Following Coronavirus-19 Vaccination:

    Data concerns and safety worries fuel crisis of confidence in AstraZeneca vaccine:

  • Covid 19 Vaccination Experience from Covid Warriors | Eternal Hospital

    4:47

    Listen from the front line warriors themselves - the Doctors, who fought brilliantly with Covid 19, and now also leading from the front in getting vaccinated, ignoring and rejecting all the rumours surrounding this Covid 19 vaccine. Also know why everyone should get vaccinated and not worry about the rumours.
    To know more, call us at +91 9549158888 or log in to for the Extra Care you deserve.
    Eternal Care, Safe Care!

  • How Hospitality Will Reinvent Itself Post-COVID | The Crexi Podcast

    56:32

    The Crexi Podcast’s latest episode features Laura Dietzel, Partner at RSM US LLP, discussing hospitality’s long and transformative road to recovery.

    The Crexi Podcast explores various aspects of the commercial real estate industry in conversation with some of the top CRE professionals in the industry. In each episode, we feature different guests to tap into their wealth of CRE expertise and explore the latest trends and updates from the world of commercial real estate.

    In this episode, Crexi’s Ryan Schlesinger sits with Laura to discuss the impact of COVID-19 on hospitality, how the industry has adapted to stay afloat amid closures and stalled travel, and what bright signs point to future recovery. Their wide-ranging conversation covers:

    - We live in a society of wanderlust, and while older generations traveled for leisure, younger ones are also doing so for work requirements and more reasons. Airbnb’s success amid the pandemic supports the resilience of the travel industry.
    - Hotels are doing anything and everything they can to ensure that they're driving occupancy opportunities, whether it's partnering with universities in the area to provide student housing or partnering with hospitals to spread out the patients recovering from coronavirus.
    - In terms of hotel valuations, ultimately, the bid-ask gap isn't as wide as it was in the early days of the pandemic. Now, hotel buyers have more information regarding vaccine rollout and how to adapt operations. Public transactions are less common, but the market is still seeing private or lender-facilitated deals for off-market hospitality properties.
    -Interestingly, bigger assets are trading at a higher volume than smaller boutique hospitality assets.


    Like this? Hop over to our blog to check out the latest CRE hot tips and insights:


    Visit The Crexi Podcast to get the latest episodes:



    Subscribe for the latest in CRE from Crexi:



    Follow Crexi:








    About Laura Dietzel:
    Laura specializes in providing real estate audit and consulting matters for privately held companies and private equity funds specializing in real estate. Since joining RSM, she has worked with commercial, residential, retail, hotels and real estate opportunity funds, as well as performed due diligence services for real estate funds and various lenders in the real estate conduit markets.

    Laura has over fifteen years of experience in real estate and public accounting, and has developed and presented multiple continuing education courses in the real estate industry. In 2018, she was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves. Laura’s analysis and research on the real estate markets have been routinely published and shared in the media.

    Connect with Laura:
    Learn more about RSM:

    About Crexi:
    Crexi is a commercial real estate (CRE) property marketing and deal management platform that combines an active marketplace for sale and for lease properties with powerful property marketing, deal management, and market intelligence tools designed to help brokers, buyers, and tenants eliminate time-consuming processes and close deals faster.

  • ???? Covid-19 Vaccine 1st Dose Oxford Astrazeneca

    6:44

    i got my 1st dose for covid19 mga ka kilay!!! #Covid19 #keepsafe

  • FEAR AND PHOBIA OF COVID-19 VACCINE: DR.S.M.ZAFEER

    11:56

    DR.S.M.ZAFEER
    PEDIATRICIAN
    Almana General Hospital-Jubail
    Saudi Arabia February 12 2021

  • Flu vaccines during COVID-19 pandemic Dr.S.M.Zafeer Pediatrician Almana General Hospital-Jubail KSA

    3:11

  • My COVID 19 vaccine experience

    3:45

    My COVID 19 vaccine experience.

    I had the Oxford–AstraZeneca COVID vaccine. The first dose.

  • OXFORD/ASTRAZENECA: GROUP CLEARS AIR ON VACCINE, URGES CITIZENS TO SUPPORT NPHCDA’S EFFORTS...!

    1:09

  • Oxford Vaccine, Moderna, CDC, Test Sensitivity and Specificity

    57:33

    Please read and agree to the disclaimer before watching this video.
    . Oxford Vaccine Reloaded, Moderna, CDC

    Oxford Vaccine US invests $1.2bln




    Moderna (5/19) Vaccine


    Moderna (5/18) Vaccine


    CanSino Vaccine


    CanSino trial




    CDC continues to “reorganize” their information page.


    Surface stability of the SARS-COV-2


    An analysis of other studies (very important to read.)



    Test sensitivity and specificity

    FDA’s list


    Another list


    Another good article for tests
    The Latest on Coronavirus Testing: New Methods, Accuracy, and Availability- GoodRx

    Good article by ASM



    A study on the rtPCR tests


    Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR primer-probe sets | medRxiv ...

    Disclaimer:
    This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
    Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional. ...
    Disclaimer:
    This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
    Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

  • Covid vaccine reactions | How everyones feeling #satire

    4:49

    Do your research from reputable sources and make the right choice! Check out one of our latest videos below:


    Thank you for watching! Don't forget to like, share and subscribe for more videos!

    #comedy #stlucia #covidvaccine #drama #caribbeanculture

  • The role of bats in RNA viruses epidemiology

    17:38

    Lecture presented at IVSA The Americas in April 11, 2021.

    Bats and RNA viruses have long co-evolved. These viruses found perfect conditions in bats, making them their main reservoirs.
    Conversely, RNA viruses are the most frequent pathogens involved in emerging diseases. Even though bats and RNA viruses are in the spotlight during the Covid-19 pandemic, little has been done to predict where, how and why the next pandemic is going to begin.
    In this lecture we will discuss the reasons of the association between bats and RNA viruses, the current status of emerging RNA viruses and chiropterofauna and what should be done to provide better and precise information about sanitary threats from bats and RNA viruses.
    Moreover, I will try to demystify the bats and make them more attractive for you to study them.

  • Covid IgG IgM Antibody Testing Lab in Ahmedabad

    53

    Covid-19 Antibody Testing Laboratory in Ahmedabad - Covid IgG IgM

    Govt of Gujarat approved testing center

    Using ICMR and US-FDA approved kit

    Fast results within 4 hours

    Quantitative report with titre value

    Test cost price : Covid IgG - Rs 500 , Covid IgM - Rs 500.

    Home visit charges extra Rs 100

    Trusted and reliable pathology laboratory in Naranpura Ahmedabad.
    For more details and booking visit

    #covidigg
    #covidigm

  • Vacunas y COVID-19

    1:38:55

    Dra Olga Arguedas (Directora del HNN) y la Dra Gabriela Ivankovich del Servicio de Inmunología, nos hablarán del controversial tema de las vacunas contra COVID19 ????⚕️????

  • Post Covid vaccine reactions part 1: do we need to be afraid?

    8:59

    Effect of Covid vaccine sa isang active person. I am a medical doctor and I wish to just share my experience with the covid vaccine. Is there a serious side effect?
    Tulad ng karamihan, isa ako sa may agam agam tungkol sa bakuna ng Covid. The only way to know is to experience it.

  • ✅ Canada to pause use of Oxford-AstraZeneca’s COVID-19 vaccine for people under age of 55: sources

    3:26

    ✅ Canada to pause use of Oxford-AstraZeneca’s COVID-19 vaccine for people under age of 55: sources
    ???? Please Subscribe:
    ???? #covid, #covid19, #astrazeneca, #astrazenecacovidvaccine, #astrazenecavaccinesuspension, #news, #canada, #coronayellow, #coronavirus, #canadaastrazeneca, #healthcanada, #yespop

    Source:

  • Pfizer vaccine potentially increases the chance of getting infected by South Africa and UK variant

    5:56

  • COVID19 VACCINE COVISHIELD AZD1222 Astrazeneca Oxford University PHARMACEUTICALCONCEPT PC

    6:23

    COVID19 VACCINE COVISHIELD AZD1222 Astrazeneca Oxford University PHARMACEUTICALCONCEPT PC

    Coronavirus has infected more than1.5 crore people across the globe since outbreak.
    No vaccine has been developed yet, to protect against the deadly novel virus.
    At present, 3 vaccine candidates are at the advanced stage of their trials.
    Among them, Oxford's COVID-19 vaccine has shown a positive result in its initial trial. According to a report published in the British medical journal, The Lancet, the COVID-19 vaccine produced a dual immune response in people aged 18 to 55.
    Officially known as AZD1222, this COVID-19 vaccine candidate has been developed by the University of Oxford and British-Swedish pharmaceutical company AstraZeneca Plc. The large-scale phase III human trials of Oxford COVID-19 vaccine has already started in Brazil.

    Doses of the vaccine were given to 1,077 healthy adults aged between 18 and 55 in five UK hospitals in April and May as part of the phase one clinical trial for the vaccine.

    1.#Phase1/2 trials successful
    2.1077 people have been involved in the clinical trials
    3.Vaccine considered as safe,well tolerated and #immunogeneic
    4.In phase 3 trial Childrens and other from diverse ethnicities will be involved
    5.Vaccine being developed by Astrazeneca & Oxford University
    6. Vaccine found to prompt “Protective #immune system”
    7. Vaccine can train immune system
    8. Only fever and headache reported as adverse symptoms
    9. UK government has already PRE-ORDERED
    First 30 million vaccine
    USA 400 million vaccines
    EU 400 million vaccines
    India’s Serum Institute has pre ordered 8 billion for India and other developing countries
    10. #chAdOx1 #virus has been used in this vaccine
    11. chAdOx1 is virus that causes common cold
    12. Coronavirus spike protein has been inserted into chAdox1 virus
    13. Scientists hope body recognises spike protein and develops immunity
    14. Speculation that B cells and #Tcells were generated in trials
    15. #Bcells produce Antibodies
    16. T cells destroy infected cells
    17. AstraZeneca has joined Serum Institute of India (SII) to produce the potential COVID-19 vaccine in India
    18. #Serum Institute will produce 3 to 4 million doses of Oxford's COVID-19 vaccine this year, Poonawalla said

    #pharmaceutical concept #PC
    19. AstraZeneca h
    as joined Serum Institute of India (SII), the world's largest vaccine

    ????Subscribe to Our Channel PHARMACEUTICAL CHANNEL
    manufacturers by number of doses produced and sold, to produce the potential vaccine. Adar Poonawalla, the chief executive officer of Serum Institute of India, said they will launch the vaccine under the brand name of Covishield if the trials are successful. The vaccine candidate is safe and prompts protective immune response, according to a report in The Lancet.
    20. There will be 4,000-5,000 participants in the phase III trial of Oxford COVID-19 vaccine in India. THE TRIAL WILL TAKE 2 MONTHS after the patients get injected and the vaccine gets a final nod by November.
    Serum Institute will manufacture up to 70 million doses of the vaccine per month up to October and plans to take it up to 100 million per month by December2020
    A coronavirus vaccine being developed at the University of Oxford 'is safe' and induces an immune response to the disease according to researchers.

    Hi friends,
    A gateway to all learners.The channel PHARMACEUTICAL CONCEPT is about the Pharmaceutical,Neutraceutical Industry, Biologics,Medical devices,Pharmaceutical Education, knowledge, and Career Opportunities (informatory ,educational channel for all around the globe.

    Target viewers Pharmaceuticals professionals working in
    ???? Quality Control
    ????Quality Assurance
    ????Production
    ????Packing
    ????Regulatory Affairs
    ????Patents (IPR)
    Watch 'Pharmaceutical Concept’-
    ♦ Subscribe to channel 'Pharmaceutical Concept’ and press the bell icon to get the notification

    ♦Like, comment & Share the video with your colleague and friends

    ❤Instagram - pharmaceutical concept

    For the advertisements, business inquiry & Online training cum certification contact us at
    I have more than 18Years of experience in pharmaceutical R&D manufacturing. I make these videos to share the knowledge
    Disclaimer:
    Videos is for educational purposes only
    ❤ THANKS FOR WATCHING ❤

    COVID19 VACCINE COVISHIELD AZD1222 Astrazeneca Oxford University
    PHARMACEUTICALCONCEPT PC

    #COVID19VACCINE #COVISHIELD #AZD1222 #Astrazeneca #OxfordUniversity #VACCINE #PHARMACEUTICALCONCEPT #PC #BHARATBIOTECH

  • Föreläsning om covid 19 och vacciner

    54:47

    Vilka risker finns med sjukdomen covid-19? Hur fungerar de olika vaccinerna mot sjukdomen och hur har det kunnat gå så snabbt att få fram dem? Hur ser riskerna för biverkningar ut och hur ska jag kunna veta vilken information jag kan lita på?

    Det är några av frågorna som forskare vid Medicinska fakulteten svarar på i denna föreläsning. Den är uppdelad i olika avsnitt:
    00:22 Michelle Chew, professor i Anestesiologi. Kort- och långtidseffekter av covid-19
    10:37 Marie Larsson, professor i Molekylär virologi. Hur fungerar vaccin?
    17:03 Jorma Hinkula, professor i Molekylär virologi. Vilken information kan jag lita på? Vilka biverkningar kan vaccinerna ge?
    41:19 Martin Ulander, överläkare neurofysiologiska kliniken, US. Vad är narkolepsi?
    45:35 Maria Jenmalm, professor i experimentell allergologi. Hur fungerar vårt immunförsvar?

    Vill du se en kortare sammanfattning?


    Andra relevanta länkar om covid-19:
    Folkhälsomyndigheten:
    1177:
    Krisinformation.se:
    Region Östergötland:
    Linköpings universitet:
    SVT om vaccin:

  • தடுப்பு மருந்து யுத்தம் | ஒரு டோஸ் விலை | Oxford AstraZeneca | Tamil Pokkisham | Vicky | TP

    16:58

    Instagram:
    Facebook:
    Email: g.vickneswaran@gmail.com
    Website:
    Mobile App Link:
    Telegram:


    நல்லதை பகிர்வோம் நல்ல சமுதாயத்தை உருவாக்குவோம்!
    தினமும் உங்கள் 10 நிமிடம் ஒதுக்குங்கள்
    மாற்றத்தை நாம் தொடங்கிவைக்கலாம்...

    Please Subscribe and Share With Your Family and Friends.

    Please Share your Articles/Title/Research: g.vickneswaran@gmail.com
    இப்படிக்கு,
    விக்கி.


    #pokkisham #TP #TamilPokkisham #tpvicky

  • Terças-feiras com a SPI – 27/04/2021

    1:30:35

    Vacinas contra a Covid-19: dos ensaios clínicos à vida real

    Coordenador de Mesa: Dr. Luis Felipe Bachur - HC/Unicamp e Diretor da SPI

    Convidado: Dr. Ricardo Palacios - Diretor de Pesquisa Clínica do Instituto Butantan

    Convidada: Dra. Lily Yin Weckx - Investigadora e Coordenadora do CRIE/Unifesp

  • Vaksin COVID-19 Konspirasi, Uji Klinis atau Kelinci Percobaan ??

    17:38

    Membuat vaksin apalagi vaksin COVID-19 tidak mudah. Kini uji coba klinis sudah menyelesaikan fase 1 dan 2, dan akan memulai fase 3. Namun respon media sosial beragam, mulai ujaran jangan mau jadi kelinci percobaan hingga teori konspirasi vaksin cina dan akal bulus industri vaksin. Sesungguhnya vaksin COVID19 ini memang perlu dibuktikan dengan uji klinis randomisasi secara ketat dan etis, bukan sekedar mencari 'kelinci percobaan.

    1:18 Gambaran umum video
    1:36 Bagaimana prinsip kerja vaksin (dan antibodi)?
    3:31 Apakah sumber vaksin harus dari virus Covid-19 Indonesia?
    7:25 Bagaimana kita tahu vaksin Covid-19 efektif? (3 fase pengujian vaksin & siapa yang cocok diuji-cobakan vaksin)
    14:16 Apa saja tipe vaksin yang diuji klinis?
    16:08 Kesimpulan

    (Terima kasih Aggy Agatha untuk penulisan time-stamp di atas untuk memudahkan review)

    Pak Ahmad adalah konsultan biologi molekuler menjelaskan duduk perkaranya. Teknologi produksi vaksin makin canggih seperti vaksin RNA yang memberikan data awal yang menarik. Tentunya vaksin konvensional menggunakan benih virus juga akan diuji, Vaksin Covid mana yang menang, kita akan menunggu. Yang jelas tidak ada konspirasi di sini, karena kemajuan dan data penelitian vaksin covid19 ini juga dikawal oleh banyak otoritas, ilmuwan independen, dan tentu saja netizen.

  • Koronavirus Aşısı Ne Zaman Çıkacak? | Nasıl Uygulanacak?????

    13:56

    Koronavirüs Mart ayı itibarıyla pandemi haline dönüştü. Peki koronavirüs aşısı ne zaman çıkacak, covid 19 aşısı nasıl uygulanacak? Uzun zamandır herkesin beklediği şey koronavirüs aşısının bir an önce bulunması. Birçok ülke koronavirüs aşı çalışmalarına başladı hatta insanlar üzerinde de aşılar deneniyor. Normalde bir aşının bulunup uygulanma süresi 10 ile 15 yıl gibi bir süreyi buluyor.

    Koronavirüs aşısının 2021 yılının ortasında uygulanabilir hale getirilmesi düşünülüyor. Covid 19 aşısı uygulanmaya başlansa bile bu soruların cevapları merakla bekleniyor;

    Aşının etkinliği % kaç olacak?
    Yaşlılarda da aşı etkili olacak mı?
    Koronavirüs aşısı güvenli olacak mı?
    Milyonlarca aşı yapılacağı için bu süreç nasıl ilerleyecek?
    Aşı tek doz mu olacak, çift doz mu olacak?

    Prof. Dr. Murat Aksoy YouTube kanalına abone olmak için:
    ????

    'Koronavirus Aşısı Ne Zaman Çıkacak? | Nasıl Uygulanacak?' videosunu beğendiyseniz, diğer videolarıma da göz atabilirsiniz:

    ????Koronavirüs Denizden ve Havuzdan Bulaşır Mı?


    ????Koronavirüs’te Normalleşme Takvimi | Normal Yaşama Ne Zaman Döneceğiz?


    ????Koronavirüs Ne Zaman Biter? - Varislerle İlgili Tüm Cevaplar | Soru - Cevap


    ????Koronavirüs'te İsveç Modeli: Bir Başarı Hikayesi Mi? | İsveç Doğru Mu Yapıyor?


    ????Ailede Kovid Varsa Nelere Dikkat Etmeliyiz? | Evdeki Hasta İçin Yapılması Gerekenler


    ????Deney: Kumaş Maskelerin Hava Geçirgenliği | Kumaş Maskeler Korur Mu?


    Prof. Dr. Murat Aksoy sosyal medya hesaplarını takip etmeyi unutmayın:
    ????Web sitesi:
    ????Instagram:
    ????Facebook:
    ????Twitter:

    Margeret Hecker's video footage is from The Age of AIDS by Frontline, PBS

  • ஆகஸ்ட் 15 COVID-19 தடுப்புமருந்து சாத்தியமா? COVID-19 vaccine update? NIRMAL| AYYAPPA| MEIYAVA

    14:30

    ஆகஸ்ட் 15 COVID-19 தடுப்புமருந்து சாத்தியமா? COVID-19 vaccine update? NIRMAL| AYYAPPA| MEIYAVA

    What is Covax? Who is researching and manufacturing it?
    How Covax is proposed to act as a vaccine?
    Why India's Covax is better than China’s killed COVID-19 vaccine?
    Who is leading the vaccine trials? UK? USA? India? Russia? China?
    How do these vaccines work?
    What history talks about vaccines and how long it took as a process?
    How a vaccine can be released in 6 weeks' time?
    For all the above questions, see this video completely.

    Research articles:
    ChAdOX1, UK


    mRNA vaccine, Moderna therapeutics, USA



    Timeline for different viral vaccines :



    ICMR, and Bharat biotech




Shares

x

Check Also

Menu